Printer Friendly

Fetal and Maternal Outcomes of Planned Pregnancy in Patients with Systemic Lupus Erythematosus: A Retrospective Multicenter Study.

1. Introduction

Compared with the general population, patients with SLE are still at high risk of adverse pregnancy outcomes (APOs) [1]. A number of studies have shown that patients with SLE are more likely to develop fetal complications, including fetal loss, preterm birth, and IUGR, compared to healthy women [2]. However, recent studies have reported that fetal outcomes are relatively favorable if lupus is stable or mildly active [3]. Moreover, the occurrence of disease flares increases during SLE pregnancies but decreases if pregnancy is delayed until disease is quiescent [4]. Currently, patients with SLE were advised to consider pregnancy during periods of inactive or stable disease [5], the so-called "planned pregnancy." However, such researches usually enrolled a small number of candidates, and data is lacking in China.

Therefore, we performed a retrospective multicenter research in South China aimed at investigating the fetal and maternal outcomes, predictors of APOs, and pregnancy-associated disease flares in women with SLE who underwent planned pregnancy and close pregnancy monitoring by a multidisciplinary team.

2. Patients and Methods

2.1. Patient Population. A total of 243 patients with SLE who underwent planned pregnancy from three tertiary hospitals in Guangzhou from December 2011 to December 2016 were included (127 pregnancies in the First Affiliated Hospital of Sun Yat-sen University; 66 pregnancies in Guangzhou First People's Hospital, the Second Affiliated Hospital of South China University of Technology; and 50 pregnancies in the Third Affiliated Hospital of Guangzhou Medical University). Only one pregnancy for each patient was included. All patients fulfilled the 1997 ACR diagnostic criteria for SLE [6]. Planned pregnancy was defined according to Chinese recommendations for perinatal management in women with SLE [7], as lupus patients who were allowed to conceive under the situation of (1) stable disease activity for at least six months; (2) dose of oral prednisone < 15 mg per day); (3) urine protein < 0.5 g/24 hours; (4) absence of major organ dysfunction; (5) discontinuation of immunosuppressants including cyclophosphamide, methotrexate, and mycophenolate mofetil for at least six months; and (6) for those who were taking leflunomide, wash-out therapy should be administered and leflunomide was withdrawn for at least six months.

2.2. Screening and Follow-Ups. All pregnant women with SLE in the Chinese tertiary hospitals were followed according to Chinese recommendations for perinatal care in high-risk women [8], namely, every four weeks up to the 28th week of gestation and every two weeks from the 28th week up to delivery. Patients who were not followed regularly or without complete records were excluded. Regular obstetric practice, blood pressure, fetal heartbeat, clinical symptoms of lupus, laboratory tests including complete blood count, routine urine test, blood biochemical test, 24-hour urine protein, complement C3 and C4, anti-dsDNA antibodies, anti-SSA antibodies, anti-SSB antibodies, antiphospholipid antibody (including anticardiolipin (aCL) antibody IgM, aCL antibody IgG, and anti-[beta]2GP1 antibody lupus anticoagulants (LAC)), and medical treatments were recorded. SLE activity was measured by the Systemic Lupus Erythematosus Pregnancy Disease Activity Index (SLEPDAI) at the first trimester, second trimester, and third trimester. The highest score was used in statistical analysis. Fetal Doppler sonography was performed every 4~8 weeks since the 16th week of gestation and every 2~4 weeks since the 28th week of gestation. Patients with positive antiphospholipid antibody were pretreated with aspirin. Patients with antiphospholipid antibody syndrome (APS) were pretreated with aspirin and low molecular heparin until delivery.

2.3. APOs. Fetal APOs include the following: (1) fetal loss, including spontaneous abortion (termination of pregnancy before the 20th week of gestation caused by natural factors), therapeutic abortion (artificial termination of pregnancy because of life-threatening progression of lupus or obstetric complications), stillbirth (intrauterine fetal demise after 20 weeks of gestation unexplained by chromosomal abnormalities, anatomic malformation, or congenital infection), and neonatal death referred to as the death of a live infant within 28 days after birth; (2) preterm birth (live birth before 37 weeks of gestation); (3) IUGR (birth weight below the 10th percentile of the Chinese population according to gestational week at delivery and fetal gender; and (4) fetal distress referred to as fetus hypoxia and acidosis, which could endanger the health of the fetus. Composite APOs were defined as the occurrence of any adverse outcomes including fetal loss, preterm birth, SGA babies, and fetal distress during gestation. Maternal APOs include the following: (1) disease flare was defined according to the International Consensus for disease flare in lupus [9], namely, new onset or worsening of specific and associated cutaneous manifestations of SLE; arthritis; one or more hemocytopenia not attributed to immunosuppressive drugs; neurological, cardiopulmonary, and renal manifestations; elevated serum creatinine in association with low-serum complement; and/or elevated titers of anti-dsDNA antibodies. Active lupus nephritis was defined according to the following: proteinuria > 0.5 g/24h, active urinary sediment (>3 red blood cells/high-power field (HPF), or >5 white blood cells/HPF, or cellular casts), or estimated creatinine clearance (CrCl) <60ml/min/1.73[m.sup.2] with active urinary sediment. Mild disease activity was defined as SLEPDAI score 5 to 9, moderate disease activity as SLEPDAI score 10 to 14, and severe disease activity as SLEPDAI score [greater than or equal to] 15. (2) Pregnancy-induced hypertension (PIH) was defined as hypertension during pregnancy, which included gestational hypertension, preeclampsia, and eclampsia. Hypertension was defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg in sitting position in at least two consecutive measurements during pregnancy. Preeclampsia was defined as a new onset of hypertension with or without proteinuria after the 20th week of gestation in a previously normotensive woman [10].

2.4. Statistical Analysis. Software SPSS 20.0 was used for data analysis. Quantitative variables were recorded as mean [+ or -] standard deviation and compared by Student's t-test. Categorical variables were described as frequency and percentage and compared by a chi-square test. Factors related to APOs at P < 0.10 in univariate analyses were entered into a multivariate logistic model. P < 0.05 was considered as statistically significant.

2.5. Ethics Statement. Since this is a retrospective study, patient's interest was not involved; therefore, no ethical approval was required. The Ethical Committees of the above three centers waived that the research could be done based on a record review without contacting the patients. A support letter was obtained from the medical director's office of the three hospitals for retrieving retrospective data from the database and records. All the information was kept confidential, and no individual identifiers were collected.

3. Results

3.1. Demographic Data and History of Pregnancy. The average age at conception was 28.9 [+ or -] 3.9 years (20 to 38 years). Duration of SLE before pregnancy was 4.4 [+ or -] 4.3 years (1.5 to 21 years). Of the 243 patients, 146 patients became pregnant for the first time and 97 patients had prior history of pregnancy. Fifty-one patients had a history of adverse pregnancy, indicated abortion (n = 25), stillbirth (n = 3), premature delivery (n =17), IUGR (n = 5), fetal distress (n = 1), and PIH (n = 5). Five patients experienced adverse pregnancy twice.

3.2. Fetal Outcomes. One hundred and fifty-seven (64.6%) patients ended in delivery without APOs, and 86 (35.4%) patients had at least one episode of APOs. Fetal APOs were shown in Table 1. In total, 12 patients (4.9%) experienced fetal loss. Spontaneous abortion, stillbirth, and therapeutic abortion accounted for one (0.4%), six (2.5%), and five (2.1%) cases, respectively. Causes of therapeutic abortion included active lupus nephritis (n = 3), severe thrombocytopenia (n = 1), and anatomic malformation (n = 1). Live birth delivery was succeeded in 231 patients (95.1%), among which 177 patients (72.8%) had term births, 54 (22.2%) had preterm births, 36 (14.8%) had IUGR, and 27 (11.1%) had fetal distress. Average birth weight was 2713.7 [+ or -] 521.3 g (790.0~4150.0g). The average weights of preterm birth and term birth were 2198.5 [+ or -] 637.1 g (790.0~3200.0g) and 2868.8 [+ or -] 359.0 g (1940.0~4150.0g), respectively. Forty-two preterm infants (42/54, 77.8%) were delivered after the 34th week of gestation. Causes of preterm births included therapeutic preterm births (23/54, 42.6%), preterm premature rupture of membranes (PPROM) (19/54, 35.2%), and spontaneous preterm births (12/54, 22.2%). Preeclampsia (n = 14), lupus flares (n = 6), IUGR (n = 6), placenta previa (n = 3), and placental abruption (n = 2) were the main causes that led to therapeutic preterm births. All the preterm infants were viable.

3.3. Maternal Outcomes. Maternal APOs were presented in Table 1. Fifty-two disease flares (21.4%) occurred, among which 8 disease flares occurred during the first trimester, 15 during the second trimester, and 29 during the third trimester. Disease activity was mild in 45 (45/52, 86.5%) patients, moderate in 6 (6/52, 11.5%), and high in 1 (1/52, 1.9%). Disease flares were presented as active lupus nephritis (41/52, 78.8%), thrombocytopenia (10/52, 19.2%), skin/ mucosa lesions (9/52, 17.3%), leukopenia (6/52, 11.5%), arthritis (6/52, 11.5%), alopecia (2/52, 3.8%), hemolytic anemia (1/52, 1.9%), and pulmonary hypertension (1/52, 1.9%). All disease flares were promptly diagnosed and treated when necessary. Of the 52 flares, 20 were treated with an increase of oral prednisone, associated with three intravenous methylprednisolone pulses. Prednisone was prescribed 10 to 15 mg per day to patients with mild disease activity, 15 to 30 mg per day to patients with moderate disease activity, and over 30 mg per day to patients with high disease activity. In total, 27 patients (11.1%) took prednisone more than 10 mg per day. Increased azathioprine dose was prescribed to three patient, and introduction of azathioprine to seven cases. One patient with severe disease flares received therapeutic abortion and was treated with cyclophosphamide subsequently. Of these 52 pregnancies, 27 ended in preterm births, 16 in IUGR, 9 in fetal distress, and 11 in fetal loss. Causes for fetal loss in patients with disease flare included therapeutic abortion (n = 5, 9.6%), spontaneous abortion (n = 1, 1.9%), and stillbirth (n = 5, 9.6%).

In this study, PIH occurred in 29 cases, among which 3 were gestational hypertension and 26 were preeclampsia. No eclampsia occurred. Of the 29 patients, fetal loss occurred in 5 patients, preterm births in 20, IUGR in 13, and fetal distress in 10. Causes for fetal loss in patients with PIH included therapeutic abortion (n = 2, 6.9%) and stillbirth (n = 3, 10.3%). Neither the incidence of spontaneous loss nor the incidence of therapeutic abortion differed between patients with disease flares and those with PIH.

3.4. Risk Factors for Fetal APOs. Table 2 reveals a comparison of clinical events as well as laboratory parameters in patients with or without composite fetal APOs. Disease flares at any time, active lupus nephritis, thrombocytopenia, LAC positivity, aCL antibody positivity, and hypocomplementemia were more likely to occur in patients with APOs. Multivariate analysis revealed that disease flares and aCL antibody positivity were risk factors for composite fetal APOs (Table 3).

Univariate analysis for respective fetal APOs was shown in Table 4. Multivariate analysis revealed that disease flares and aCL antibody positivity were risk factors for fetal loss. Disease flares and PIH were responsible for preterm birth. PIH was also the independent predictor of IUGR and fetal distress.

3.5. Risk Factors for Maternal APOs. The rates of disease flares, active lupus nephritis, thrombocytopenia, leukopenia, LAC positivity, aCL antibody positivity, and hypocomplementemia were higher in mothers with PIH than those without (Table 5). Multivariate analysis revealed that disease flares, thrombocytopenia, and aCL antibody positivity were independent predictors of PIH.

4. Discussion

Herein, we leveraged a retrospective multicenter study on planned pregnancy in women with SLE. All patients were in inactive or stable state prior to conception and followed by a multidisciplinary team of experts. In our research, two-thirds of the pregnancies ended in successful delivery without any fetal APOs and severe maternal disease flares occurred in only 0.4%. Our results showed that the rate of fetal loss was significantly decreased and the occurrence of moderate-to-severe disease flares was remarkably reduced in lupus patients who underwent planned pregnancy, although preterm births remained an important issue.

Our study showed that 4.9% of the pregnancies ended in fetal loss. In comparison, a meta-analysis by Smyth et al. including 37 studies with 1842 patients and 2751 pregnancies, whose disease activity was not strictly controlled prior to pregnancy, revealed that the rate of fetal loss was as high as 23.4% [11]. Our previous research also indicated that 28.5% of pregnancies in the general lupus patients ended in fetal loss, which was significantly higher than that in women undergoing planned pregnancy. Two prospective studies evaluating fetal outcomes in lupus patients in a stable disease state reported approximate rates of fetal loss to our study, indicating 8.4% and 4.0%, respectively [3, 12]. All the three researches, ours included, suggested that planned pregnancy was beneficial for decreasing fetal loss. The above meta-analysis also revealed a higher preterm rate in women with SLE who did not undergo planned pregnancy (39.4%) [11]. In our research, the rate of preterm birth (22.2%) exceeded that in the Chinese general population (6.2~7.2%) [13], comparable to the results from the multicenter prospective study by Clowse et al. mainly focusing on lupus patients with inactive or mild stable disease state (28.2%) [14]. In our research, most preterm births occurred after the 34th week of gestation with favorable outcomes. No neonatal death occurred. Planned pregnancy, partially by decreasing the preterm rate, could improve the overall outcomes of infants in women with SLE. PPROM is considered as the primary cause for preterm birth in the general population, followed by therapeutic or spontaneous preterm [15]. Different from the general population, in our research, therapeutic preterm was the primary cause for preterm birth. Preeclampsia and disease flares are the major causes that lead to therapeutic preterm. Therefore, disease evaluation and blood pressure monitoring is of great importance.

Major risk factors for APOs in SLE pregnancy have been investigated in multiple studies and generally fall into three categories: renal involvement, SLE disease activity, and presence of aPL antibodies [16]. In our research, risk factors for fetal APOs included disease flares during pregnancy and aCL positivity, consistent with previous findings. Our results showed that fetal loss was strongly associated with both disease flares during pregnancy and the presence of aCL. It was reported that high disease activity increased the risk of fetal loss fourfold [17]. In this study, an approximate 66.7% of pregnant patients who had fetal loss were aCL antibody-positive, compared to 9.1% in the group with live births. A previous report also pointed out that there was an increased risk in fetal loss in mothers with aCL antibodies [18]. Our study indicated that disease flares during pregnancy and PIH were responsible for preterm births in patients with SLE, consistent with previous findings [19]. A prospective research also demonstrated that a high SLEDAI score increased the possibility of preterm delivery [3]. Increase in blood pressure is associated with preterm births [20] and low offspring birth weight [21] according to previous findings. In healthy pregnant women, hypertension increases the likelihood of placenta dysfunction, resulting in fetal intrauterine distress and fetal growth restriction [22,23]. A similar association was found in our research, showing that PIH contributed to an increased risk of IUGR and fetal distress. Overall, this data suggested that maintaining inactive disease during pregnancy, treating with positive aCL antibodies, and controlling blood pressure were important for successful pregnancy.

We observed mild-moderate flares in 21.0% of pregnancies and severe flares in 0.4%, a total of 21.4%. A multicenter prospective trial assessing maternal outcomes of pregnant women with slightly active or inactive lupus nephritis before pregnancy reported that mild-to-moderate disease flares occurred in 18.3% and severe flares in 1.4% of pregnancies, which were comparable to our findings [4]. It suggested that lupus patients undergoing planned pregnancy experienced less severe disease flares with more favorable consequences. Therefore, early recognition and prompt treatment are necessary during pregnancy and could improve disease outcomes.

In our research, the rate of PIH (11.9%) was approximately twice over the general population in China (5.2%) [24]. A retrospective study of 103 pregnancies in Chinese patients with SLE found higher frequencies of PIH (20.0%) in SLE women without planned pregnancy [25]. The PROMISSE study also demonstrated that patients with inactive disease at conception had lower rates of PIH (11.2%). In our research, the independent risk factors for PIH included disease flares during pregnancy, thrombocytopenia, and aCL positivity. Active disease was the strongest predictor of preeclampsia, consistent with previous studies [4]. A systematic review indicated that there is an association between aCL antibodies and severe preeclampsia [26].

In conclusion, our research showed that planned pregnancy improved fetal and maternal outcomes in lupus patients, presenting as lower rates of fetal loss, more favorable outcomes for preterm infants, and less severe disease flares during pregnancy. Our research reinforced the importance of planned pregnancy, which allowed women with SLE to conceive in a proper time monitored by multidisciplinary experts. Disease flares should be recognized and treated immediately in order to prevent severe complications. Blood pressure should be closely controlled during pregnancy.


An earlier version of this work has been presented as an abstract at the Annual European Congress of Rheumatology, 2018, according to the following link: content/annrheumdis/77/Suppl_2/1468.2.full.pdf.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

Dongying Chen and Minxi Lao contributed equally to this work.


This project was supported by grants from the Guangdong Science and Technology Project (2016A020215043), Guangzhou Science and Technology Plan Project (201607010145), and the National Natural Science Foundation of China (81603435, 81601403).


[1] M. E. B. Clowse, M. Jamison, E. Myers, and A. H. James, "A national study of the complications of lupus in pregnancy," American Journal of Obstetrics & Gynecology, vol. 199, no. 2, pp. 127.e1-127.e6, 2008.

[2] P. K. Bundhun, M. Z. S. Soogund, and F. Huang, "Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001-2016," Journal of Autoimmunity, vol. 79, pp. 17-27, 2017.

[3] G. Moroni, A. Doria, E. Giglio et al., "Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study," Journal of Autoimmunity, vol. 74, pp. 6-12, 2016.

[4] G. Moroni, A. Doria, E. Giglio et al., "Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter-study," Journal of Autoimmunity, vol. 74, pp. 194-200,2016.

[5] L. Andreoli, G. K. Bertsias, N. Agmon-Levin et al., "EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome," Annals of the Rheumatic Diseases, vol. 76, no. 3, pp. 476-485, 2017.

[6] M. C. Hochberg, "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus," Arthritis and Rheumatism, vol. 40, no. 9, p. 1725, 1997.

[7] The SLE study group of China, "Chinese recommendations for perinatal management in women with SLE," National Medical Journal of China, vol. 95, pp. 1056-1060, 2015.

[8] Obstetrics and Gynecology Group of Chinese Medical Association, "Chinese recommendations for perinatal care in high-risk women (1st edition)," Chinese Journal of Obstetrics and Gynecology, vol. 46, pp. 150-153, 2011.

[9] N. Ruperto, L. M. Hanrahan, G. S. Alarcon et al., "International consensus for a definition of disease flare in lupus," Lupus, vol. 20, no. 5, pp. 453-462, 2011.

[10] M. A. Brown, M. D. Lindheimer, M. de Swiet, A. Van Assche, and J.-M. Moutquin, "The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)," Hypertension in Pregnancy, vol. 20, no. 1, pp. IX-XIV, 2001.

[11] A. Smyth, G. H. M. Oliveira, B. D. Lahr, K. R. Bailey, S. M. Norby, and V. D. Garovic, "A systematic review and metaanalysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis," Clinical Journal of the American Society of Nephrology, vol. 5, no. 11, pp. 2060-2068, 2010.

[12] J. P. Buyon, M. Y. Kim, M. M. Guerra et al., "Predictors of pregnancy outcome in a prospective, multiethnic cohort of lupus patients," Annals of Internal Medicine, vol. 163, no. 3, pp. 153-163, 2015.

[13] H. Blencowe, S. Cousens, M. Z. Oestergaard et al., "National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications," Lancet, vol. 379, no. 9832, pp. 2162-2172, 2012.

[14] M. E. B. Clowse, D. J. Wallace, M. Weisman, A. James, L. G. Criscione-Schreiber, and D. S. Pisetsky, "Predictors of preterm birth in patients with mild systemic lupus erythematosus," Annals of the Rheumatic Diseases, vol. 72, no. 9, pp. 1536-1539, 2013.

[15] L. E. Simmons, C. E. Rubens, G. L. Darmstadt, and M. G. Gravett, "Preventing preterm birth and neonatal mortality: exploring the epidemiology, causes, and interventions," Seminars in Perinatology, vol. 34, no. 6, pp. 408-415, 2010.

[16] L. R. Sammaritano, "Management of systemic lupus erythematosus during pregnancy," Annual Review of Medicine, vol. 68, no. 1, pp. 271-285, 2017.

[17] M. E. B. Clowse, L. S. Magder, F. Witter, and M. Petri, "The impact of increased lupus activity on obstetric outcomes," Arthritis and Rheumatism, vol. 52, no. 2, pp. 514-521, 2005.

[18] C. M. Yelnik, C. A. Laskin, T. F. Porter et al., "Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results," Lupus Science & Medicine, vol. 3, no. 1, article e000131, 2016.

[19] T. F. Chiu, Y. W. Chuang, C. L. Lin et al., "Long-term outcomes of systemic lupus erythematous patients after pregnancy: a nationwide population-based cohort study," PLoS One, vol. 11, no. 12, article e0167946, 2016.

[20] R. Bakker, E. A. P. Steegers, A. Hofman, and V. W. V. Jaddoe, "Blood pressure in different gestational trimesters, fetal growth, and the risk of adverse birth outcomes: the generation R study," American Journal of Epidemiology, vol. 174, no. 7, pp. 797-806, 2011.

[21] C. Macdonald-Wallis, K. Tilling, A. Fraser, S. M. Nelson, and D. A. Lawlor, "Associations of blood pressure change in pregnancy with fetal growth and gestational age at delivery: findings from a prospective cohort," Hypertension, vol. 64, no. 1, pp. 36-44, 2014.

[22] R. Townsend, P. O'Brien, and A. Khalil, "Current best practice in the management of hypertensive disorders in pregnancy," Integrated Blood Pressure Control, vol. 9, pp. 79-94, 2016.

[23] A. R. Vest and L. S. Cho, "Hypertension in pregnancy," Current Atherosclerosis Reports, vol. 16, no. 3, p. 395, 2014.

[24] C. Ye, Y. Ruan, L. Zou et al., "The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes," PLoS One, vol. 9, no. 6, article e100180, 2014.

[25] L. W. Kwok, L. S. Tam, T. Zhu, Y. Y. Leung, and E. Li, "Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus," Lupus, vol. 20, no. 8, pp. 829-836, 2011.

[26] K. Abou-Nassar, M. Carrier, T. Ramsay, and M. A. Rodger, "The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and metaanalysis," Thrombosis Research, vol. 128, no. 1,pp. 77-85,2011.

Dongying Chen, (1) Minxi Lao, (2) Jianyu Zhang, (3) Yanfeng Zhan, (4) Weinian Li, (5) Xiaoyan Cai (ID), (5) and Zhongping Zhan

(1) Department of Rheumatology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou 510080, China

(2) Department of Rheumatology and Department of Geriatrics, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou 510080, China

(3) Department of Rheumatology, The Third Affiliated Hospital of Guangzhou Medical University, No. 63, Duobao Road, Guangzhou 510150, China

(4) Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou 510080, China

(5) Department of Rheumatology, Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, No. 1, Panfu Road, Guangzhou 510180, China

Correspondence should be addressed to Xiaoyan Cai; and Zhongping Zhan;

Received 22 November 2017; Accepted 11 July 2018; Published 3 September 2018

Academic Editor: Bogdan Kolarz
Table 1: Maternal and fetal outcomes in pregnant
women with SLE.

Fetal adverse events              N     %

Preterm birth                     54   22.2
Intrauterine growth retardation   36   14.8
Fetal distress                    27   11.1
Fetal loss                        12   4.9
  Spontaneous abortion            1    0.4
  Therapeutic abortion            5    2.1
  Stillbirth                      6    2.5
  Neonatal death                  0     0
Maternal adverse events
Disease flares                    52   21.4
  In the first trimester          8    3.3
  In the second trimester         15   6.2
  In the third trimester          29   11.9
SLEPDAI max > 4
  5~9                             45   18.5
  10~14                           6    2.5
  [greater than or equal to] 15   1    0.4
Pregnancy-induced hypertension    29   11.9
  Gestational hypertension        3    1.2
  Preeclampsia                    26   10.7
  Eclampsia                       0     0

Table 2: Association of different characteristics during
pregnancy with composite fetal APOs.

Characteristics                   Total       With fetal
                                 (n = 243)   APOs (n = 86)

Clinical manifestation at any
  time (n, %)
Flare during pregnancy           52 (21.4)     40 (46.5)
Active lupus nephritis           45 (18.5)     32 (37.2)
Thrombocytopenia                 23 (9.5)      14 (16.3)
Leukopenia                        7 (2.9)       4 (4.7)
Skin rash                        19 (7.8)       9 (10.5)
Joint involvement                18 (7.4)       6 (7.0)
Serological profile at any
  time (n, %)
Anti-dsDNA antibody positivity   93 (38.3)     34 (39.5)
Anti-Ro antibody positivity      50 (20.6)     19 (22.1)
Anti-La antibody positivity      33 (13.6)     12 (14.0)
LAC positivity                   19 (7.8)      14 (16.3)
aCL IgG positivity               25 (10.3)     21 (24.4)
aCL IgM positivity               13 (5.3)      11 (12.8)
Anti-beta2 GP1 positivity        21 (8.6)       7 (8.1)
Hypoalbuminemia                  66 (27.2)     29 (33.7)
C3 < 80 mg/dL                    40 (16.5)     24 (27.9)
C4 < 15 mg/dL                    51 (21.0)     29 (33.7)

Characteristics                  Without fetal    P value
                                 APOs (n = 157)

Clinical manifestation at any
  time (n, %)
Flare during pregnancy              12 (7.6)      <0.001
Active lupus nephritis              13 (8.3)      <0.001
Thrombocytopenia                     9 (5.7)       0.01
Leukopenia                           3 (1.9)       0.2
Skin rash                           10 (6.4)       0.3
Joint involvement                   12 (7.6)       0.9
Serological profile at any
  time (n, %)
Anti-dsDNA antibody positivity     59 (37.6)       0.8
Anti-Ro antibody positivity        31 (19.8)       0.7
Anti-La antibody positivity        21 (13.4)       1.0
LAC positivity                      5 (3.2)       <0.001
aCL IgG positivity                  4 (2.5)       <0.001
aCL IgM positivity                  2 (1.3)       <0.001
Anti-beta2 GP1 positivity          14 (8.9)        0.8
Hypoalbuminemia                    37 (23.6)       0.09
C3 < 80 mg/dL                      16 (10.2)      <0.001
C4 < 15 mg/dL                      22 (14.0)      <0.001

Table 3: Association of different characteristics during pregnancy
with APOs: results of multivariate analysis.

Characteristics                       P value    OR    OR 95% CI

Fetal APOs
Composite APOs
Disease flares during pregnancy       <0.001    8.1    3.8-17.2
Anticardiolipin antibody positivity   <0.001    7.4    2.5-21.8
Fetal loss
Disease flares during pregnancy        0.002    28.4   3.4-239.0
Anticardiolipin antibody positivity    0.004    7.8    1.9-31.4
Preterm birth
Disease flares during pregnancy        0.002    3.5     1.6-7.7
PIH                                   <0.001    6.0    2.3-15.8
PIH                                   <0.001    6.7    2.9-15.8
Fetal distress
PIH                                   <0.001    6.1    2.5-15.2
Maternal APOs
Disease flares during pregnancy       <0.001    12.2   4.4-33.3
Thrombocytopenia                       0.04     4.0    1.1-14.8
aCL antibody positivity               <0.001    7.5    2.5-22.4

Table 4: Univariate analysis of variables associated with
different fetal adverse maternal outcomes.

Characteristics                         Yes       Fetal       P

n                                        12        231        --
Disease flares during pregnancy       11(91.7)   41(17.7)   <0.001
Active lupus nephritis                9(75.0)    36(15.6)   <0.001
Thrombocytopenia                      5(41.7)    18(7.8)    0.002
Leukopenia                            2(16.7)     5(2.2)     0.04
PIH                                   5(41.7)    24(10.4)   0.007
Anti-dsDNA antibody positivity        5(41.7)    88(38.1)    0.8
Anti-Ro antibody positivity           8(66.7)    91(39.4)    0.07
Anti-La antibody positivity           2(16.7)    31(13.4)    0.7
LAC positivity                        5(41.7)    14(6.1)    0.001
Anticardiolipin antibody positivity   8(66.7)    21(9.1)    <0.001
Anti-beta2 GP1 positivity             2(16.7)    19(8.2)     0.3
Hypoalbuminemia                       6(50.0)    60(26.0)    0.09
Hypocomplementemia                    9(75.0)    47(20.3)   <0.001
Hydroxychloroquine                    9(75.0)    117(50.6)   0.1

Characteristics                         Yes      Preterm      P

n                                        54        189        --
Disease flares during pregnancy       27(50.0)   25(13.2)   <0.001
Active lupus nephritis                23(42.6)   22(11.6)   <0.001
Thrombocytopenia                      8(14.8)    15(7.9)     0.1
Leukopenia                             2(3.7)     5(2.6)     0.7
PIH                                   20(37.0)    9(4.8)    <0.001
Anti-dsDNA antibody positivity        21(38.9)   72(38.1)    1.0
Anti-Ro antibody positivity           21(38.9)   78(41.3)    0.8
Anti-La antibody positivity           8(14.8)    25(13.2)    0.8
LAC positivity                        8(14.8)    11(5.8)     0.03
Anticardiolipin antibody positivity   15(27.8)   14(7.4)    <0.001
Anti-beta2 GP1 positivity              4(7.4)    17(9.0)     0.7
Hypoalbuminemia                       17(31.5)   49(25.9)    0.4
Hypocomplementemia                    17(31.5)   39(20.6)    0.1
Hydroxychloroquine                    29(53.7)   97(51.3)    0.8

Characteristics                         Yes      IUGR No      P

n                                        36        207        --
Disease flares during pregnancy       16(44.4)   36(17.4)   <0.001
Active lupus nephritis                12(33.3)   33(15.9)    0.01
Thrombocytopenia                      4(11.1)    19(9.2)     0.8
Leukopenia                               0        7(3.4)     0.3
PIH                                   13(36.1)   16(7.7)    <0.001
Anti-dsDNA antibody positivity        16(44.4)   77(37.2)    0.4
Anti-Ro antibody positivity           17(47.2)   82(39.6)    0.4
Anti-La antibody positivity           5(13.9)    28(13.5)    1.0
LAC positivity                        4(11.1)    15(7.2)     0.4
Anticardiolipin antibody positivity   7(25.9)    22(10.2)    0.03
Anti-beta2 GP1 positivity              2(5.6)    19(9.2)     0.7
Hypoalbuminemia                       7(19.4)    59(28.5)    0.3
Hypocomplementemia                    10(27.8)   46(22.2)    0.3
Hydroxychloroquine                    16(44.4)   46(22.2)    0.3

Characteristics                         Yes       Fetal       P

n                                        27        216
Disease flares during pregnancy       9(33.3)    43(19.9)    0.1
Active lupus nephritis                7(25.9)    38(17.6)    0.3
Thrombocytopenia                      5(18.5)    18(8.3)     0.2
Leukopenia                             1(3.7)     6(2.8)     0.6
PIH                                   10(37.0)   19(8.8)    <0.001
Anti-dsDNA antibody positivity        9(33.3)    84(38.9)    0.6
Anti-Ro antibody positivity           16(59.3)   83(38.3)    0.04
Anti-La antibody positivity           3(11.1)    30(13.9)    0.7
LAC positivity                        4(14.8)    15(6.9)     0.2
Anticardiolipin antibody positivity   9(25.0)    20(9.7)     0.02
Anti-beta2 GP1 positivity              2(7.4)    19(8.8)     0.8
Hypoalbuminemia                       7(25.9)    59(27.3)    0.9
Hypocomplementemia                    6(22.2)    50(23.1)    0.9
Hydroxychloroquine                    11(40.7)   115(53.)    0.2

Table 5: Univariate analysis of variables associated with adverse
maternal outcomes.


Characteristics                         Yes         No       P value
                                      (n = 29)   (n = 214)

Disease flares during pregnancy       22(75.9)   30(14.0)    <0.001
Active lupus nephritis                18(62.1)   27(12.6)    <0.001
Thrombocytopenia                      9(31.0)     14(6.5)    <0.001
Leukopenia                            3(10.3)     4(1.9)      0.04
Anti-dsDNA antibody positivity        12(41.4)   81(37.9)      0.7
Anti-Ro antibody positivity           14(48.3)   85(39.7)      0.4
Anti-La antibody positivity            2(6.9)    31(14.5)      0.4
LAC positivity                        7(24.1)     12(5.6)     0.003
Anticardiolipin antibody positivity   15(51.7)    14(6.5)    <0.001
Anti-beta2 GP1 positivity              1(3.4)     20(9.3)      0.5
Hypoalbuminemia                       11(37.9)   55(25.7)      0.2
Hypocomplementemia                    14(48.3)   42(19.6)     0.001
Hydroxychloroquine                    13(44.8)   113(52.8)     0.4
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Chen, Dongying; Lao, Minxi; Zhang, Jianyu; Zhan, Yanfeng; Li, Weinian; Cai, Xiaoyan; Zhan, Zhongping
Publication:Journal of Immunology Research
Date:Jan 1, 2018
Previous Article:Role of Mast Cells and Type 2 Innate Lymphoid (ILC2) Cells in Lung Transplantation.
Next Article:PYR-41 and Thalidomide Impair Dendritic Cell Cross-Presentation by Inhibiting Myddosome Formation and Attenuating the Endosomal Recruitments of p97...

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters